AbbVie Quarterly Income Statements Chart
Quarterly
|
Annual
AbbVie Quarterly Income Statements Table
Quarterly
|
Annual
Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-06-30 | 2013-03-31 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
net revenues | 15,423,000,000 | 13,343,000,000 | 15,102,000,000 | 14,460,000,000 | 14,462,000,000 | 12,310,000,000 | 14,301,000,000 | 13,927,000,000 | 13,865,000,000 | 12,225,000,000 | 15,121,000,000 | 14,812,000,000 | 14,583,000,000 | 13,538,000,000 | 14,886,000,000 | 14,342,000,000 | 13,959,000,000 | 13,010,000,000 | 13,858,000,000 | 12,902,000,000 | 10,425,000,000 | 8,619,000,000 | 8,704,000,000 | 8,479,000,000 | 8,255,000,000 | 7,828,000,000 | 8,305,000,000 | 8,236,000,000 | 8,278,000,000 | 7,934,000,000 | 7,739,000,000 | 6,995,000,000 | 6,944,000,000 | 6,538,000,000 | 6,796,000,000 | 6,432,000,000 | 6,452,000,000 | 5,958,000,000 | 5,944,000,000 | 5,475,000,000 | |||||
yoy | 6.65% | 8.39% | 5.60% | 3.83% | 4.31% | 0.70% | -5.42% | -5.97% | -4.92% | -9.70% | 1.58% | 3.28% | 4.47% | 4.06% | 7.42% | 11.16% | 33.90% | 50.95% | 59.21% | 52.16% | 26.29% | 10.10% | 4.80% | 2.95% | -0.28% | -1.34% | 7.31% | 17.74% | 19.21% | 21.35% | 13.88% | 8.75% | 7.63% | 9.73% | 14.33% | 17.48% | |||||||||
qoq | 15.59% | -11.65% | 4.44% | -0.01% | 17.48% | -13.92% | 2.69% | 0.45% | 13.42% | -19.15% | 2.09% | 1.57% | 7.72% | -9.06% | 3.79% | 2.74% | 7.29% | -6.12% | 7.41% | 23.76% | 20.95% | -0.98% | 2.65% | 2.71% | 5.45% | -5.74% | 0.84% | -0.51% | 4.34% | 2.52% | 10.64% | 0.73% | 6.21% | -3.80% | 5.66% | -0.31% | 8.29% | 0.24% | 8.57% | ||||||
cost of products sold | 4,346,000,000 | 4,002,000,000 | 4,396,000,000 | 4,212,000,000 | 4,202,000,000 | 4,094,000,000 | 5,704,000,000 | 6,485,000,000 | 4,240,000,000 | 3,986,000,000 | 4,170,000,000 | 5,022,000,000 | 4,170,000,000 | 4,052,000,000 | 4,320,000,000 | 4,390,000,000 | 4,523,000,000 | 4,213,000,000 | 4,684,000,000 | 5,050,000,000 | 3,711,000,000 | 1,942,000,000 | 2,006,000,000 | 1,920,000,000 | 1,819,000,000 | 1,694,000,000 | 2,022,000,000 | 1,835,000,000 | 1,934,000,000 | 1,927,000,000 | 2,280,000,000 | 1,616,000,000 | 1,528,000,000 | 1,616,000,000 | 1,555,000,000 | 1,504,000,000 | 1,405,000,000 | 1,369,000,000 | 1,167,000,000 | 916,000,000 | 1,094,000,000 | 1,113,000,000 | 1,100,000,000 | 1,054,000,000 | 1,153,000,000 |
gross profit | 11,077,000,000 | 9,341,000,000 | 10,706,000,000 | 10,248,000,000 | 10,260,000,000 | 8,216,000,000 | 8,597,000,000 | 7,442,000,000 | 9,625,000,000 | 8,239,000,000 | 10,951,000,000 | 9,790,000,000 | 10,413,000,000 | 9,486,000,000 | 10,566,000,000 | 9,952,000,000 | 9,436,000,000 | 8,797,000,000 | 9,174,000,000 | 7,852,000,000 | 6,714,000,000 | 6,677,000,000 | 6,698,000,000 | 6,559,000,000 | 6,436,000,000 | 6,134,000,000 | 6,283,000,000 | 6,401,000,000 | 6,344,000,000 | 6,007,000,000 | 5,459,000,000 | 5,379,000,000 | 5,416,000,000 | 4,922,000,000 | 5,241,000,000 | 4,928,000,000 | 5,047,000,000 | 4,589,000,000 | 4,777,000,000 | 4,559,000,000 | |||||
yoy | 7.96% | 13.69% | 24.53% | 37.70% | 6.60% | -0.28% | -21.50% | -23.98% | -7.57% | -13.15% | 3.64% | -1.63% | 10.35% | 7.83% | 15.17% | 26.74% | 40.54% | 31.75% | 36.97% | 19.71% | 4.32% | 8.85% | 6.61% | 2.47% | 1.45% | 2.11% | 15.09% | 19.00% | 17.13% | 22.04% | 4.16% | 9.15% | 7.31% | 7.26% | 9.71% | 8.09% | |||||||||
qoq | 18.58% | -12.75% | 4.47% | -0.12% | 24.88% | -4.43% | 15.52% | -22.68% | 16.82% | -24.76% | 11.86% | -5.98% | 9.77% | -10.22% | 6.17% | 5.47% | 7.26% | -4.11% | 16.84% | 16.95% | 0.55% | -0.31% | 2.12% | 1.91% | 4.92% | -2.37% | -1.84% | 0.90% | 5.61% | 10.04% | 1.49% | -0.68% | 10.04% | -6.09% | 6.35% | -2.36% | 9.98% | -3.94% | 4.78% | ||||||
gross margin % | 71.82% | 70.01% | 70.89% | 70.87% | 70.94% | 66.74% | 60.11% | 53.44% | 69.42% | 67.39% | 72.42% | 66.10% | 71.41% | 70.07% | 70.98% | 69.39% | 67.60% | 67.62% | 66.20% | 60.86% | 64.40% | 77.47% | 76.95% | 77.36% | 77.96% | 78.36% | 75.65% | 77.72% | 76.64% | 75.71% | 70.54% | 76.90% | 78.00% | 75.28% | 77.12% | 76.62% | 78.22% | 77.02% | 80.37% | 83.27% | |||||
selling, general and administrative | 3,253,000,000 | 3,293,000,000 | 3,855,000,000 | 4,205,000,000 | 3,377,000,000 | 3,315,000,000 | 3,193,000,000 | 3,372,000,000 | 3,268,000,000 | 3,039,000,000 | 3,417,000,000 | 3,304,000,000 | 5,412,000,000 | 3,127,000,000 | 3,260,000,000 | 3,083,000,000 | 3,164,000,000 | 2,842,000,000 | 3,231,000,000 | 2,846,000,000 | 3,527,000,000 | 1,695,000,000 | 1,951,000,000 | 1,657,000,000 | 1,654,000,000 | 1,680,000,000 | 1,929,000,000 | 1,919,000,000 | 1,760,000,000 | 1,791,000,000 | 1,951,000,000 | 1,452,000,000 | 1,504,000,000 | 1,368,000,000 | 1,653,000,000 | 1,381,000,000 | 1,466,000,000 | 1,355,000,000 | 1,474,000,000 | 1,703,000,000 | 1,595,000,000 | 1,448,000,000 | 1,340,000,000 | 1,406,000,000 | 1,237,000,000 |
research and development | 2,131,000,000 | 2,067,000,000 | 6,774,000,000 | 2,130,000,000 | 1,948,000,000 | 1,939,000,000 | 1,927,000,000 | 1,723,000,000 | 1,733,000,000 | 2,292,000,000 | 1,790,000,000 | 1,614,000,000 | 1,609,000,000 | 1,497,000,000 | 1,827,000,000 | 1,673,000,000 | 1,802,000,000 | 1,782,000,000 | 1,890,000,000 | 1,706,000,000 | 1,582,000,000 | 1,379,000,000 | 1,542,000,000 | 2,285,000,000 | 1,291,000,000 | 1,289,000,000 | 6,495,000,000 | 1,268,000,000 | 1,322,000,000 | 1,244,000,000 | 1,402,000,000 | 1,222,000,000 | 1,223,000,000 | 1,135,000,000 | 1,190,000,000 | 1,106,000,000 | 1,124,000,000 | 946,000,000 | 1,418,000,000 | 981,000,000 | 812,000,000 | 834,000,000 | 772,000,000 | 709,000,000 | 634,000,000 |
acquired ipr&d and milestones | 823,000,000 | 248,000,000 | 1,574,000,000 | 82,000,000 | 937,000,000 | 164,000,000 | 282,000,000 | 66,000,000 | 280,000,000 | 150,000,000 | 243,000,000 | 40,000,000 | 269,000,000 | 145,000,000 | |||||||||||||||||||||||||||||||
other operating income | -24,000,000 | -169,000,000 | -10,000,000 | -172,000,000 | -68,000,000 | ||||||||||||||||||||||||||||||||||||||||
total operating costs and expenses | 10,529,000,000 | 9,610,000,000 | 16,592,000,000 | 10,629,000,000 | 10,464,000,000 | 9,512,000,000 | 11,106,000,000 | 11,646,000,000 | 9,352,000,000 | 9,457,000,000 | 9,619,000,000 | 10,209,000,000 | 11,288,000,000 | 8,821,000,000 | 9,812,000,000 | 10,036,000,000 | 9,518,000,000 | 8,907,000,000 | 10,105,000,000 | 9,647,000,000 | 9,673,000,000 | 5,016,000,000 | 4,748,000,000 | 5,862,000,000 | 4,855,000,000 | 4,818,000,000 | 10,746,000,000 | 5,077,000,000 | 5,516,000,000 | 5,031,000,000 | 5,945,000,000 | 4,290,000,000 | 4,270,000,000 | 4,119,000,000 | 4,438,000,000 | 4,071,000,000 | 4,065,000,000 | 3,680,000,000 | 4,059,000,000 | 3,623,000,000 | 4,059,000,000 | 3,411,000,000 | 3,212,000,000 | 3,239,000,000 | 3,024,000,000 |
operating earnings | 4,894,000,000 | 3,733,000,000 | -1,490,000,000 | 3,831,000,000 | 3,998,000,000 | 2,798,000,000 | 3,195,000,000 | 2,281,000,000 | 4,513,000,000 | 2,768,000,000 | 5,502,000,000 | 4,603,000,000 | 3,295,000,000 | 4,717,000,000 | 5,074,000,000 | 4,306,000,000 | 4,441,000,000 | 4,103,000,000 | 3,753,000,000 | 3,255,000,000 | 752,000,000 | 3,603,000,000 | 3,956,000,000 | 2,617,000,000 | 3,400,000,000 | 3,010,000,000 | -2,441,000,000 | 3,159,000,000 | 2,762,000,000 | 2,903,000,000 | 1,794,000,000 | 2,705,000,000 | 2,674,000,000 | 2,419,000,000 | 2,358,000,000 | 2,361,000,000 | 2,387,000,000 | 2,278,000,000 | 1,885,000,000 | 1,852,000,000 | 960,000,000 | 1,515,000,000 | 1,351,000,000 | 1,453,000,000 | 1,305,000,000 |
interest expense | 678,000,000 | 627,000,000 | 610,000,000 | 591,000,000 | 506,000,000 | 453,000,000 | 378,000,000 | 398,000,000 | 454,000,000 | 454,000,000 | 476,000,000 | 497,000,000 | 532,000,000 | 539,000,000 | 571,000,000 | 585,000,000 | 606,000,000 | 622,000,000 | 618,000,000 | 620,000,000 | 614,000,000 | 428,000,000 | 455,000,000 | 420,000,000 | 309,000,000 | 325,000,000 | 319,000,000 | 302,000,000 | 272,000,000 | 251,000,000 | 252,000,000 | 252,000,000 | 253,000,000 | 247,000,000 | 290,000,000 | 250,000,000 | 225,000,000 | 200,000,000 | 197,000,000 | 164,000,000 | 128,000,000 | 69,000,000 | 65,000,000 | ||
net foreign exchange loss | 23,000,000 | 4,000,000 | 1,000,000 | 4,000,000 | 49,000,000 | 25,000,000 | 37,000,000 | 35,000,000 | 40,000,000 | 36,000,000 | 47,000,000 | 25,000,000 | 16,000,000 | 12,000,000 | 14,000,000 | 9,000,000 | 17,000,000 | 20,000,000 | 29,000,000 | 5,000,000 | 11,000,000 | 19,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 2,000,000 | 8,000,000 | 8,000,000 | 6,000,000 | 13,000,000 | 15,000,000 | 302,000,000 | 13,000,000 | 14,000,000 | 174,000,000 | 5,000,000 | 3,000,000 | 14,000,000 | 15,000,000 | ||||||
other income | 2,639,000,000 | 1,441,000,000 | 150,000,000 | 1,159,000,000 | 1,345,000,000 | 586,000,000 | 1,556,000,000 | -95,000,000 | 1,412,000,000 | 1,804,000,000 | 2,021,000,000 | -330,000,000 | 1,533,000,000 | -776,000,000 | 216,000,000 | 21,000,000 | 2,658,000,000 | -395,000,000 | 4,625,000,000 | 115,000,000 | 802,000,000 | 72,000,000 | 135,000,000 | 500,000,000 | -153,000,000 | 29,000,000 | 349,000,000 | 62,000,000 | 73,000,000 | 38,000,000 | 101,000,000 | 250,000,000 | 8,000,000 | ||||||||||||
earnings before income tax expense | 1,554,000,000 | 1,661,000,000 | -2,269,000,000 | 2,084,000,000 | 2,146,000,000 | 1,755,000,000 | 1,212,000,000 | 1,953,000,000 | 2,610,000,000 | 475,000,000 | 2,965,000,000 | 4,400,000,000 | 1,183,000,000 | 4,929,000,000 | 4,271,000,000 | 3,688,000,000 | 1,163,000,000 | 3,867,000,000 | -1,507,000,000 | 2,500,000,000 | -693,000,000 | 3,098,000,000 | 1,338,000,000 | 2,001,000,000 | 807,000,000 | 2,544,000,000 | 1,892,500,000 | 2,761,000,000 | 2,012,000,000 | 2,797,000,000 | 1,193,000,000 | 2,095,000,000 | 2,353,000,000 | 2,086,000,000 | 1,998,000,000 | 2,014,000,000 | 2,096,000,000 | 1,776,000,000 | 1,647,000,000 | 1,678,000,000 | 687,000,000 | 1,433,000,000 | 1,286,000,000 | 1,368,000,000 | 1,239,000,000 |
income tax expense | 613,000,000 | 372,000,000 | 419,000,000 | 520,000,000 | 773,000,000 | 383,000,000 | 388,000,000 | 172,000,000 | 583,000,000 | 234,000,000 | 284,750,000 | 448,000,000 | 255,000,000 | 436,000,000 | 303,500,000 | 508,000,000 | 394,000,000 | 312,000,000 | 80,250,000 | 187,000,000 | 46,000,000 | 88,000,000 | 67,750,000 | 117,000,000 | 66,000,000 | 88,000,000 | 14,250,000 | 14,000,000 | 29,000,000 | 14,000,000 | 1,141,000,000 | 464,000,000 | 438,000,000 | 375,000,000 | 607,000,000 | 416,000,000 | 486,000,000 | 422,000,000 | 408,000,000 | 312,000,000 | 181,000,000 | 335,000,000 | 306,000,000 | 300,000,000 | 271,000,000 |
net earnings | 941,000,000 | 1,289,000,000 | -23,000,000 | 1,564,000,000 | 1,373,000,000 | 1,372,000,000 | 824,000,000 | 1,781,000,000 | 2,027,000,000 | 241,000,000 | 2,472,000,000 | 3,952,000,000 | 928,000,000 | 4,493,000,000 | 4,045,000,000 | 3,180,000,000 | 769,000,000 | 3,555,000,000 | 38,000,000 | 2,313,000,000 | -739,000,000 | 3,010,000,000 | 2,801,000,000 | 1,884,000,000 | 741,000,000 | 2,456,000,000 | -1,826,000,000 | 2,747,000,000 | 1,983,000,000 | 2,783,000,000 | 52,000,000 | 1,631,000,000 | 1,915,000,000 | 1,711,000,000 | 1,391,000,000 | 1,598,000,000 | 1,610,000,000 | 1,354,000,000 | 1,239,000,000 | 1,366,000,000 | 506,000,000 | 1,098,000,000 | 980,000,000 | 1,068,000,000 | 968,000,000 |
net earnings attributable to noncontrolling interest | 3,000,000 | 3,000,000 | -1,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 2,000,000 | 3,000,000 | 3,000,000 | 2,000,000 | -1,000,000 | 3,000,000 | 4,000,000 | 3,000,000 | 1,000,000 | 1,000,000 | 3,000,000 | 2,000,000 | 2,000,000 | 5,000,000 | |||||||||||||||||||||||||
net earnings attributable to abbvie inc. | 938,000,000 | 1,286,000,000 | -22,000,000 | 1,561,000,000 | 1,370,000,000 | 1,369,000,000 | 822,000,000 | 1,778,000,000 | 2,024,000,000 | 239,000,000 | 2,473,000,000 | 3,949,000,000 | 924,000,000 | 4,490,000,000 | 4,044,000,000 | 3,179,000,000 | 766,000,000 | 3,553,000,000 | 36,000,000 | 2,308,000,000 | -738,000,000 | ||||||||||||||||||||||||
yoy | -31.53% | -6.06% | -102.68% | -12.20% | -32.31% | 472.80% | -66.76% | -54.98% | 119.05% | -94.68% | -38.85% | 24.22% | 20.63% | 26.37% | 11133.33% | 37.74% | -203.79% | ||||||||||||||||||||||||||||
qoq | -27.06% | -5945.45% | -101.41% | 13.94% | 0.07% | 66.55% | -53.77% | -12.15% | 746.86% | -90.34% | -37.38% | 327.38% | -79.42% | 11.03% | 27.21% | 315.01% | -78.44% | 9769.44% | -98.44% | -412.74% | |||||||||||||||||||||||||
net income margin % | 6.08% | 9.64% | -0.15% | 10.80% | 9.47% | 11.12% | 5.75% | 12.77% | 14.60% | 1.96% | 16.35% | 26.66% | 6.34% | 33.17% | 27.17% | 22.17% | 5.49% | 27.31% | 0.26% | 17.89% | -7.08% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |||||
per share data | |||||||||||||||||||||||||||||||||||||||||||||
basic earnings per share attributable to abbvie inc. | 0.52 | 0.72 | -0.01 | 0.88 | 0.77 | 0.77 | 0.46 | 1 | 1.14 | 0.13 | 1.39 | 2.22 | 0.52 | 2.52 | 2.27 | 1.78 | 0.42 | 2 | -0.05 | 1.3 | -0.46 | ||||||||||||||||||||||||
diluted earnings per share attributable to abbvie inc. | 0.52 | 0.72 | -0.02 | 0.88 | 0.77 | 0.77 | 0.46 | 1 | 1.14 | 0.13 | 1.39 | 2.21 | 0.51 | 2.51 | 2.26 | 1.78 | 0.42 | 1.99 | -0.05 | 1.29 | -0.46 | ||||||||||||||||||||||||
weighted-average basic shares outstanding | 1,768 | 1,768 | 1,769 | 1,769 | 1,768 | 1,769 | 1,768 | 1,767 | 1,767 | 1,770 | 1,771 | 1,771 | 1,770 | 1,771 | 1,770 | 1,770 | 1,769 | 1,769 | 1,667 | 1,769 | 1,647 | 1,481 | 1,481 | 1,481 | 1,480 | 1,480 | 1,541 | 1,511 | 1,568 | 1,591 | 1,596 | 1,597 | 1,595 | 1,597 | 1,622 | 1,632 | 1,624 | 1,616 | 1,652 | 1,620 | 1,595 | 1,594 | 1,595 | 1,589 | 1,588 |
weighted-average diluted shares outstanding | 1,771 | 1,772 | 1,773 | 1,772 | 1,771 | 1,773 | 1,773 | 1,771 | 1,771 | 1,776 | 1,778 | 1,776 | 1,776 | 1,778 | 1,777 | 1,777 | 1,776 | 1,775 | 1,673 | 1,774 | 1,647 | 1,484 | 1,484 | 1,483 | 1,484 | 1,483 | 1,546 | 1,515 | 1,572 | 1,596 | 1,603 | 1,603 | 1,600 | 1,603 | 1,631 | 1,640 | 1,632 | 1,625 | 1,664 | 1,633 | 1,610 | 1,608 | 1,609 | 1,609 | 1,605 |
net foreign exchange gain | 500,000 | -3,000,000 | 7,000,000 | 9,000,000 | 78,250,000 | -4,000,000 | |||||||||||||||||||||||||||||||||||||||
other operating expense | -1,000,000 | 229,000,000 | 108,000,000 | 500,000,000 | |||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development | 405,000,000 | 390,000,000 | 97,000,000 | 70,000,000 | 300,000,000 | 45,000,000 | 853,000,000 | 139,000,000 | 91,000,000 | 155,000,000 | 300,000,000 | 55,000,000 | 69,000,000 | 312,000,000 | 15,000,000 | 40,000,000 | 80,000,000 | 70,000,000 | 10,000,000 | 23,000,000 | 308,000,000 | 16,000,000 | 70,000,000 | ||||||||||||||||||||||
net income attributable to noncontrolling interest | -1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||
basic earnings per share | 2.02 | 1.89 | 1.27 | 0.49 | 1.65 | -1.14 | 1.81 | 1.26 | 1.74 | 0.03 | 1.02 | 1.2 | 1.07 | 0.86 | 0.97 | 0.99 | 0.83 | 0.75 | 0.84 | 0.32 | 0.69 | 0.61 | 0.67 | 0.61 | |||||||||||||||||||||
diluted earnings per share | 2.02 | 1.87 | 1.26 | 0.49 | 1.65 | -1.13 | 1.81 | 1.26 | 1.74 | 0.03 | 1.01 | 1.19 | 1.06 | 0.85 | 0.97 | 0.98 | 0.83 | 0.74 | 0.83 | 0.31 | 0.68 | 0.61 | 0.66 | 0.6 | |||||||||||||||||||||
cash dividends declared per common share | 0.96 | 0.96 | 0.71 | 0.64 | 0.64 | 0.64 | 0.64 | 0.57 | 0.57 | 0.57 | 0.51 | 0.51 | 0.42 | 0.42 | 0.42 | 0.4 | 0.8 | ||||||||||||||||||||||||||||
other income (income) | 51,000,000 | 28,000,000 | |||||||||||||||||||||||||||||||||||||||||||
net sales | 5,019,000,000 | 4,926,000,000 | 4,563,000,000 | 4,692,000,000 | 4,329,000,000 | ||||||||||||||||||||||||||||||||||||||||
interest income | 75,000,000 | 66,000,000 |
We provide you with 20 years income statements for AbbVie stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AbbVie stock. Explore the full financial landscape of AbbVie stock with our expertly curated income statements.
The information provided in this report about AbbVie stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.